The reason why the usefulness of Arg2 inhibitors against GI cancer is arguable is epitomized by a study in which Arg2 deficiency exacerbated gastric immunopathology during chronic gastritis (51, 52). The gene discussed is ARG2; the disease is chronic gastritis.